Akebia Therapeutics Enters License Agreement With Medice Arzneimittel Pütter For Commercialization Of Vafseo For Treatment Of Anemia Associated With CKD In Europe And Australia; Co. To Receive $10M Upfront Payment And Up To $100M In Milestones
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics has entered a license agreement with Medice Arzneimittel Pütter for the commercialization of Vafseo, a treatment for anemia associated with CKD, in Europe and Australia. Akebia will receive a $10 million upfront payment and up to $100 million in milestones.
May 25, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akebia Therapeutics signed a license agreement with Medice for Vafseo commercialization, receiving a $10M upfront payment and up to $100M in milestones.
The license agreement with Medice will provide Akebia Therapeutics with a significant upfront payment and potential milestone payments, which will positively impact the company's revenue and financial position. This partnership also expands the commercialization of Vafseo to Europe and Australia, increasing the potential market for the treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100